2Nazimek-Siewniak B,Moczulski D,Grzeszczak W.Risk of macrovascular and microvascular complications in Type 2 diabetes:results of longitudinal study design.J Diabetes Complications,2002,16:271-276.
3V.Mohan.Vascular complications in long-term South Indian NIDDM of over 25 years' duration.Diabetes Research and Clinical Practice,1996,31:133-140.
4Klein R,Palta M,Allen C,et al.Incidence of retinopathy and associated risk factors from time of diagnosis of insulin-dependent diabetes.Arch Ophthalmol,1997,115:351-356.
5Motala AA,Pirie FJ,Gouws E,et al.Microvascular complications in South African patients with long-duration diabetes mellitus.S Afr Med J,2001,91:987-992.
6Pinna C,Cignarella A,Zanardo R,et al.Gender differences and antioxidant treatment affect aortic reactivity in short-term diabetic rats.Eur J Pharmacol.2001,431:71-79.
7Chang C,Lu F,Yang YC,et al.Epidemiologic study of type 2 diabetes in Taiwan.Diabetes Res Clin Pract,2000,50 (Suppl 2):S49-S59.
5Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary[J]. Control Clin Trials, 1996,1"7(1): 1 -12.
7Pinzur M S. Diabetic peripheral neuropathy[J].Foot and ankle clinics,2011,(02):345.
8Hoffman DL,Sadosky A,Dukes EM. How do changes in pain severity levels correspond to changes in health status and function in patients with painful diabetic peripheral neuropathy[J].{H}PAIN,2010,(02):194.
9Sharma U,Griesing T,Emir B. Time to onset of neuropathic pain reduction:a retrospective analysis of data from nine controlled trials of pregabalin for painful diabetic peripheral neuropathy and postherpetic neuralgia[J].{H}American Journal of Therapeutics,2010,(06):577-585.
10Schwartz S,Etropolski M,Shapiro D Y. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy:Results of a randomized-withdrawal,placebo-controlled trial[J].Current Medical Research & Opinion,2010,(01):151-162.
